List of Gene Therapy Companies in Belgium - 12

BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of immunity, auto-immune diseases and organ repair.

Cell Matters is a company operating in the cell therapy industry that enhances cell therapy productivity through cryopreservation services and GMP compliance.

Our mission is to enhance access to medical treatment by delivering excellence in the design and execution of clinical trials. DICE is a Contract Research Organization with over 30 years of experience in the execution of clinical trials. We have assisted in the execution of Phase I-IV studies and supported in the defense at EMA and FDA with clients from across the globe. We have expertise in an array of therapeutic areas and experience in the development of different medical technologies. DICE offers a variety of services including: Clinical Study Design, Clinical Data Management, Biostatistical Analysis, Medical Writing, Central Imaging Review, and Medical Monitoring. Our knowledgeable and dedicated team of experts have a drive and curiosity that encourages them to take on projects as if they were their own. At DICE, your success is our own success. For more information, visit www.dice-cro.com

EsoBiotec is a biotechnology company developing an in vivo engineering platform to produce cancer fighting cells inside the patient's body.

Exothera is a contract research, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of viral vectors and nucleic acids. At Exothera and Univercells, Our mission is to make life-changing therapies available to all. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide custom-made process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera selects technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing. Company number: 0744643660 VAT: BE0744643660

Ovizio Imaging Systems, founded in 2009, is a Belgian company that provides the bioprocessing industry with a unique PAT for gathering insight into their cell culture process. The Ovizio platform utilizes label-free, non-destructive, holographic microscopy to detect changes in cell morphology, which is recorded by the microscope and interpreted by AI into meaningful data. The bio-connect, a single-use disposable, allows for closed-loop travel of the cells between the bioreactor and the instrument for analysis. Some applications of interest include cell density and viability metrics, cell counting of cells on microcarriers, transduction or transfection efficiency, cell subtype differentiation, cell activation, and early stage bacterial or fungi contamination. Ovizio’s flagship instrument, the iLineF Pro, is GMP qualified and is commonly used in the cell & gene therapy industry where it is deployed in manufacturing, as well as process development.

Genome editing-based therapies become the predominant technology of the 21st century with promising statements about genetic diseases treatments. Genome editing tools recently emerged but they suffer from an absence of standardization and their applications remain limited. In this context, Quidditas developed a novel genome editing platform which permits an absolute genetic recombination. Compatible with a larger scope of applications, from bioprocess improvement to genetic disorders treatment, this revolutionary technique will have a major impact in the synthetic Bio field. So "Let's cure from the beginning!"

Rejuvenate Biomed is a clinical-stage company dedicated to the discovery and development of therapeutics to prevent or delay the onset of multiple age-related diseases. Founded in 2017, Rejuvenate Biomed is a privately-held platform and pipeline company developing safe and proprietary combination drugs that help people healthy for life. By using platform technologies, Rejuvenate Biomed identifies safe compounds that influence the aging process. Novel combination drugs are discovered that have the potential to prevent or delay the onset of multiple age-related diseases. Rejuvenate Biomed confirms prediction data in preclinical models and in clinical studies. Rejuvenate Biomed’s lead drug candidate RJx-01 is currently in Phase 1b for the treatment of sarcopenia, the progressive age-associated loss of muscle function and mass.

UCB – Inspired by patients. Driven by science. At UCB, we put our heart, soul and skills into making a difference for people living with severe diseases. We look to transform patients’ lives by pushing the boundaries of what is possible. With us, our talents makes the most of who they are, unlocking innovation and setting new standards for patients. Everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” And to find the answers, we connect globally with patients and their families living with the physical and social burdens of severe disease. These connections give us new perspectives, drive our innovation, and offer a hope for a new generation of therapies that will help to transform lives. UCB – The Facts With approximately 9000 employees in around 40 countries, we are a global biopharmaceutical company headquartered in Brussels, Belgium which invests more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. A few other reasons that make UCB an amazing place to work: - Promising pipeline that includes several novel molecules; - 2023 Key Financials: € 5.3 billion global revenue Specialties: Neurology, Immunology

For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientists and entrepreneurs creating transformative platforms for the pharmaceutical and biotech industry, through technology, bioprocess know-how and entrepreneurial spirit.

Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow. Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 with the support of the Univercells group.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With 10,000 team members across 50 sites worldwide, West helps support our customers by delivering billions of components and devices each year. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index.